New research published in JAMA reports that lonafarnib, a farnesyltransferase inhibitor (FTI), extended survival in patients with Hutchinson-Gilford progeria syndrome (HGPS), or progeria.
New research published in JAMA reports that lonafarnib, a farnesyltransferase inhibitor (FTI), extended survival in patients with Hutchinson-Gilford progeria syndrome (HGPS), or progeria.
HGPS, which has an estimated incidence of 1 per 4 million births and a prevalence of 1 in 20 million living people, is an ultra rare, fatal disease that causes premature aging in children. HGPS is caused single base pathogenic variants in the LMNA gene that result in the production of a mutant lamin A protein, progerin.
No drugs are currently approved to treat HGPS, but the newly published cohort study reports that treatment with lonafarnib monotherapy is associated with lower mortality versus no treatment.
The observational cohort study, of which the primary study outcome was all-cause mortality, compared treated patients with contemporaneous untreated participants. Treatment cohorts included patients from 2 single-group, single-site clinical trials: the completed ProLon1 (n = 27) and ongoing ProLon2 (n = 36). Treated patients received oral lonafarnib at a dose of 150 mg/m2 twice per day. Untreated patients originated from a separate natural history study (n = 103).
The researchers report that untreated patients with HGPS had mean and median survival ages of 14.5 and 14.6 years, respectively. In the first treatment trial, there was 1 death (3.7%) among 27 patients in the treated group and there were 9 deaths (33.3%) among 27 patients in the matched untreated group. The conditional unadjusted hazard ratio (HR) for mortality rates of treated versus untreated patients was 0.12 (95% CI, 0.01-0.93; P =.04). Median follow-up time was 2.2 years (interquartile range [IQR], 1.9-2.2) for treated patients and 2.1 years (IQR, 1.0-2.2) for untreated patients.
In an analysis of the combined trials, mortality was statistically significantly lower in treated patients than untreated patients; there were 4 deaths (6.3%) among 63 patients in the treated group and 17 deaths (27.0%) among 63 patients in the matched untreated group. The random-effects meta-analytical conditional HR for treated versus matched untreated patients across the 2 studies was 0.23 (95% CI, 0.06-0.90; P =.04). Median follow-up time was 2.2 years (IQR, 1.4-2.3) for treated patients and 1.7 years (IQR, 0.6-2.2) for untreated patients. In a post hoc analysis of treatment trial 2, there was no significant difference in mortality between the treated and untreated patients (HR, 0.33; 95% CI, 0.07-1.59; P =.17).
The authors conclude that, among patients with HGPS, lonafarnib monotherapy was associated with a lower mortality rate after 2.2 years of follow-up, and longer-term effects of therapy will be a valuable area for study given the potential for lifelong treatment with this drug.
"This study published in JAMA shows for the first time that we can begin to put the brakes on the rapid aging process for children with Progeria," said Leslie Gordon, MD, PhD, co-founder and medical director of the Progeria Research Foundation (PRF), and lead study author. "These results provide new promise and optimism to the Progeria community.”
Reference
Gordon LB, Shappell H, Massaro J, et al. Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford progeria syndrome. JAMA. 2018;319(16):1687-1695. doi:10.1001/jama.2018.3264.
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Contributor: How Patients and Caregivers Can Be a Catalyst for Rare Disease Innovation
November 5th 2023Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.
Read More